Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH) . Mecasermin rinfabate... Mecasermin rinfabate is similar to DB01277 in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1).
- Mechanism
- Curator reviewed · 1 reference
Mecasermin rinfabate supplies recombinant-DNA-origin IGF-1 (rhIGF-1) bound to recombinant-DNA-origin IGFBP-3. 80% of IGF-1 is naturally bound to IGFBP-3 so the binding of rhIGF-1 to rhIGFBP-3 increases the half life of rhIGF-1 compared to DB01277. rhIGF-1 binds to the Type I IGF-1 receptor. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth.
- Primary indication
- Mecasermin rinfabate was approved for treatment of severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH).Curator reviewed · 2 structured indications
- Also known as
- Mecasermin rinfabate recombinant
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Mecasermin rinfabate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account